Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREB1 | P16220 | 4/20 | 0.74 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.69 |
| ▸ | SLCO2B1 | O94956 | 1/20 | 0.60 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.60 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.60 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.60 |
| ▸ | FLT3 | P36888 | 1/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | PTPRS | Q13332 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL973080 | 0.97 | CREB1 (0.72) | CREB1ABCB1SLCO2B1PRSS1PRSS2 | |
| SCHEMBL971876 | 0.96 | CREB1 (0.71) | CREB1ABCB1 | |
| SCHEMBL973259 | 0.96 | CREB1 (0.71) | CREB1ABCB1 | |
| SCHEMBL972945 | 0.94 | CREB1 (0.83) | CREB1ABCB1SLCO2B1PRSS1PRSS2 | |
| SCHEMBL971911 | 0.88 | CREB1 (0.80) | CREB1ABCB1SLCO2B1PRSS1PRSS2 | |
| SCHEMBL972759 | 0.88 | ABCB1 (0.89) | CREB1ABCB1ABCG2 | |
| SCHEMBL971797 | 0.87 | CREB1 (0.82) | CREB1ABCB1SLCO2B1PRSS1PRSS2 | |
| SCHEMBL970349 | 0.85 | CREB1 (1.00) | CREB1ABCB1SLCO2B1PRSS1PRSS2 | |
| SCHEMBL973395 | 0.84 | ABCB1 (0.87) | ABCB1 | |
| SCHEMBL974036 | 0.83 | ABCB1 (0.85) | ABCB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875650-B2 | Baicalein analogs; enhances bioavailability of active compounds, especially orally administered compounds, by inhibition of P-glycoprotein 170 (P-gp 170) and/or CYP450 enzyme; 6-Acetoxy-5,7-dihydroxyflavone | YALE UNIVERSITY (US) | 2011-01-25 | — | — | US | disclosed |
| US-20070161605-A1 | Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring | YALE UNIVERSITY (US) | 2007-07-12 | — | — | US | disclosed |
| WO-2005075449-A1 | COMPOUNDS AND METHODS TO INCREASE ANTI-P-GLYCOPROTEIN ACTIVITY OF BAICALEIN BY ALKYLATION ON THE A RING | YALE UNIVERSITY (US) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161605-A1 | Compounds and methods to increase anti-p-glycoprotein activity of baicalein by alkylation on the a ring | ABCB1, ABCB11, ABCG2 | CREB1 2524/4885ABCB1 1/4885SLCO2B1 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.